Attenuation of Salt-Loading Induced Cardiomegaly and Dyslipidemia in Wistar Rats by Aqueous Leaf Extract of Chromolaena odorata


The effect of aqueous extract of the leaves of Chromolaena odorata on body weight, organ sizes, lipid profiles and atherogenic indices was investigated in normal and sub-chronic salt-loaded rats. The normal and treatment control groups were fed 100% of commercial feed, while the test control, reference and test treatment groups received an 8% salt-loaded diet. The extract (at 100 and 200 mg/kg body weight) and moduretics (at 1 mg/kg body weight) were orally administered daily. The normal and test control groups orally received appropriate volumes of water. The extract was screened for bioactive components using gas chromatography-coupled-flame ionization detector. The main glycosides, saponins, allicins, alkaloids, benzoic acid derivatives, terpenes and lignans detected were arbutin, avenacin B-1 (and avenacin A-1), diallyl thiosulphinate, lupanine, ferulic acid (and vanillic acid), limonene and retusin, respectively. Compared to test control, the extract dose-dependently, significantly (P < 0.05) lowered the heart size, plasma levels of triglyceride, total density lipoprotein, very low density lipoprotein, low density lipoprotein and non-high density lipoprotein cholesterol and atherogenic indices (cardiac risk ratio, atherogenic coefficient and atherogenic index of plasma). It also significantly increased plasma high density lipoprotein level. These results suggest a protective mechanism of the extract against hypertension induced cardiomegaly and dyslipidemia, thus suggesting that this may underlie its antihypertensive action.

Share and Cite:

J. Ikewuchi, C. Ikewuchi and M. Ifeanacho, "Attenuation of Salt-Loading Induced Cardiomegaly and Dyslipidemia in Wistar Rats by Aqueous Leaf Extract of Chromolaena odorata," Pharmacology & Pharmacy, Vol. 5 No. 2, 2014, pp. 160-170. doi: 10.4236/pp.2014.52022.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] G. Kabakci, N. Koylan, B. Ilerigelen, O. Kozan and K Buyukozturk, on Behalf of the ICEBERG Investigators, “Impact of Dyslipidemia on Cardiovascular Risk Stratification of Hypertensive Patients and Association of Lipid Profile with other Cardiovascular Risk Factors: Results from the ICEBERG Study,” Integrated Blood Pressure Control, Vol. 1, No. 1, 2008, pp. 5-13.
[2] Y. Zhao, C. Wang, J. Wu, Y. Wang, W. Zhu, Y. Zhang and Z. Du, “Choline Protects against Cardiac Hypertrophy Induced by Increased After-Load,” International Journal of Biological Science, Vol. 9, No. 3, 2013, pp. 295-302.
[3] R. Kelishadi, “Dyslipidemia from Prevention to Treatment,” InTech, Croatia, 2012.
[4] M. Vokurková, Z. Dobesová, J. Kunes and J. Zicha, “Membrane Ion Transport in Erythrocytes of Salt Hypertensive Dahl Rats and Their F2 Hybrids: The Importance of Cholesterol,” Hypertension Research, Vol. 26, No. 5, 2003, pp. 397-404.
[5] J. Zicha, Z. Dobesová, M. Vokurková, H. Rauchová, S. Hojná, M. Kadlecová, M. Behuliak, I. Vaněcková and J. Kunes, “Age-Dependent Salt Hypertension in Dahl Rats: Fifty Years of Research,” Physiology Research, Vol. 61, No. Suppl. 1, 2012, pp. S35-S87.
[6] H. Bernardes-Silva, O. Toffoletto, L. A. Bortolotto, M. C. M. Latrilha, E. M. Krieger, F. Pileggi and R. C. Maranhão, “Malignant Hypertension Is Accompanied by Marked Alterations in Chylomicron Metabolism,” Hypertension, Vol. 26, No. 6, 1995, pp. 1207-1210.
[7] P. S. Sever, B. Dahlöf, N. R. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S. E. Kjeldsen, A. Kristinsson, G. T. McInnes, J. Mehlsen, M. Nieminen, E. O’Brien and J. Östergren, for the ASCOT Investigators, “Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients Who Have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,” Lancet, Vol. 361, No. 9364, 2003, pp. 1149-1158.
[8] J. B. Leikin and M. S. Lipsky, “American Medical Association Complete Medical Encyclopedia,” Random House Reference, New York, 2003.
[9] C. Ferreira Filho, L. C. de Abreu, V. E. Valenti, M. Ferreira, A. Meneghini, J. A. Silveira, A. R. Pérez Riera, E. Colombari, N. Murad, P. R. Santos-Silva, L. J. H. Pereira da Silva, L. C. M. Vanderlei, T. D. Carvalho and C. Ferreira, “Anti-Hypertensive Drugs Have Different Effects on Ventricular Hypertrophy Regression,” Clinics, Vol. 65, No. 7, 2010, pp. 723-728.
[10] K. Urbanek, F. Quaini, G. Tasca, D. Torella, C. Castaldo, B. Nadal-Ginard, A. Leri, J. Kajstura, E. Quaini and P. Anversa, “Intense Myocyte Formation from Cardiac Stem Cells in Human Cardiac Hypertrophy,” Proceedings of the National Academy of Science USA, Vol. 100, No. 18, 2003, pp. 10440-10445.
[11] E. A. Bregagnollo, K. Okoshi, I. F. Bregagnollo, C. R. Padovani, M. P. Okoshi and A. C. Cicogna, “Effects of the Prolonged Inhibition of the Angiotensin-Converting Enzyme on the Morphological and Functional Characteristics of Left Ventricular Hypertrophy in Rats with Persistent Pressure Overload,” Arquivos Brasileiros de Cardiologia, Vol. 84, No. 3, 2005, pp. 225-232.
[12] P. Verdecchia, F. Angeli, P. Achilli, C. Castellani, A. Broccatelli, R. Gattobigio and C. Cavallini, “Echocardiographic Left Ventricular Hypertrophy in Hypertension: Marker for Future Events or Mediator of Events?” Current Opinions in Cardiology, Vol. 22, No. 4, 2007, pp. 329-334. doi:10.1097/HCO.0b013e328
[13] A. S. Wierzbicki, “Lipid Lowering: Another Method of Reducing Blood Pressure?” Journal of Human Hypertension, Vol. 16, No. 11, 2002, pp. 753-760.
[14] M. Pandey, M. Debnath, S. Gupta and S. K. Chikara, “Phytomedicine: An Ancient Approach Turning into Future Potential Source of Therapeutics,” Journal of Pharmacognosy and Phytotherapy, Vol. 3, No. 3, 2011, pp. 27-37.
[15] P. Juretschke, W. F. Vogel and G. Riess, “Strategies in Drug Discovery and Evaluation,” In: H. G. Vogel, Ed., Drug Discovery and Evaluation: Pharmacological Assays, 3rd Edition, Springer-Verlag, New York, 2008, pp. 1-45.
[16] M. T. Yakubu, “Effect of a 60-Day Oral Gavage of a Crude Alkaloid Extract from Chromolaena odorata Leaves on Hormonal and Spermatogenic Indices of Male Rats,” Journal of Andrology, Vol. 33, No. 6, 2012, pp. 1199-1207.
[17] The State of Queensland, Department of Agriculture, Fisheries and Forestry, “Siam Weed (Chromolaena odorata), Declared Class 1 Pest Plant,” Fact Sheet PP49, Department of Agriculture, Fisheries and Forestry Biosecurity Queensland, 2013.
[18] J. C. Ikewuchi, C. C. Ikewuchi, E. C. Enuneku, S. A. Ihunwo, O. I. Osayande, D. B. Batubo and D. I. D. Manuel, “Alteration of Blood Pressure Indices and Pulse Rates by an Aqueous Extract of the Leaves of Chromolaena odorata (L) King and Robinson (Asteraceae),” Pacific Journal of Science and Technology, Vol. 13, No. 2, 2012, pp. 348-358.
[19] O. O. Oluwaniyi and S. A. Ibiyemi, “A Study of the Extractability of Thevetia Glycosides with Alcohol Mixture,” Journal of Food Technology, Vol. 5, No. 2, 2007, pp. 147-151.
[20] M. Guo, L. Zhang and Z. Liu, “Analysis of Saponins from Leaves of Aralia elata by Liquid Chromatography and Multi-stage Tandem Mass Spectrometry,” Analytical Science, Vol. 25, No. 6, 2009, pp. 753-758.
[21] J. Roy, D. M. Shakleya, P. S. Callery and J. G. Thomas, “Chemical Constituents and Antimicrobial Activity of a Traditional Herbal Medicine Containing Garlic and Black Cumin,” African Journal of Traditional, Complementary and Alternative Medicines, Vol. 3, No. 2, 2006, pp. 1-7.
[22] N. T. C. Tram, M. Mitova, V. Bankova, N. Handjieva and S. S. Popov, “GC-MS of Crinum latifolium L. Alkaloids,” Zeitschrift für Naturforschung, Vol. 57c, 2002, pp. 239-242.
[23] A. Ortan, M.-L. Popescu, A.-L. Gaita, C. Dinu-PIrvu and G. H. Campeanu, “Contributions to the Pharmacognostical Study on Anethum graveolens, Dill (Apiaceae),” Romanian Biotechnological Letters, Vol. 14, No. 2, 2009, pp. 4342-4348.
[24] D. O. Ndoumou, G. T. Ndzomo and P. F. Djocgoue, “Changes in Carbohydrate, Amino Acid and Phenol Contents in Cocoa Pods from three Clones after Infection with Phytophthora megakarya Bra. and Grif,” Annals of Botany, Vol. 77, No. 2, 1996, pp. 153-158.
[25] J. M. Chapman, C. Knoy, K. Kindscher, R. C. D. Brown and S. Niemann, “Identification of Antineoplastic and Neurotrophic Lignans in Medicinal Prairie Plants by Liquid Chromatography Electron Impact Mass Spectrometry (LC/EI/MS),” Life Sciences, 2006.
[26] P. C. M. Obiefuna, O. A. Sofola and A. B. Ebeigbe, “Dietary Salt-Loading Attenuates Endothelium Dependent Relaxation in Response to Histamine but Not to Acetylcholine in Rat Aortic Rings,” Experimental Physiology, Vol. 76, No. 1, 1991, pp. 135-138.
[27] W. T. Friedewald, R. I. Levy and D. S. Friedrickson, “Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, without Use of the Preparative Ultracentrifuge,” Clinical Chemistry, Vol. 18, No. 6, 1972, pp. 499-502.
[28] J. D. Brunzell, M. Davidson, C. D. Furberg, R. D. Goldberg, B. V. Howard, J. H. Stein and J. L. Witztum, “Lipoprotein Management in Patients with Cardiometabolic Risk: Consensus Conference Report from the American Diabetes Association and the American College of Cardiology Foundation,” Journal of the American College of Cardiology, Vol. 51, No. 15, 2008, pp. 1512-1524.
[29] J. C. Ikewuchi, E. N. Onyeike, A. A. Uwakwe and C. C. Ikewuchi, “Effect of Aqueous Extract of the Leaves of Acalypha wilkesiana ‘Godseffiana’ Muell Arg (Euphorbiaceae) on the Hematology, Plasma Biochemistry and Ocular Indices of Oxidative Stress in Alloxan Induced Diabetic Rats,” Journal of Ethnopharmacology, Vol. 137, No. 3, 2011, pp. 1415-1424.
[30] C. G. Brilla, “Regression of Myocardial Fibrosis in Hypertensive Heart Disease: Diverse Effects of Various Antihypertensive Drugs,” Cardiovascular Research, Vol. 46, No. 2, 2000, pp. 324-331.
[31] P. A. Van Zwieten, “The Influence of Antihypertensive Drug Treatment on the Prevention and Regression of Left Ventricular Hypertrophy,” Cardiovascular Research, Vol. 45, No. 1, 2000, pp. 82-91.
[32] A. C. Sposito, “Emerging Insights into Hypertension and Dyslipidaemia Synergies,” European Heart Journal, Vol. 6, Suppl. G, 2004, pp. G8-G12.
[33] K. E. Ferrier, M. H. Muhlmann, J. P. Baguet, J. D. Cameron, G. L. Jennings, A. M. Dart and B. A. Kingwell, “Intensive Cholesterol Reduction Lowers Blood Pressure and Large Artery Stiffness in Isolated Systolic Hypertension,” Journal of the American College of Cardiology, Vol. 39, No. 6, 2002, pp. 1020-1025.
[34] Scottish Intercollegiate Guidelines Network, “Risk Estimation and the Prevention of Cardiovascular Disease. A National Clinical Guideline,” Scottish Intercollegiate Guidelines Network, Edinburgh, 2007.
[35] J. L. Adolphe, S. J. Whiting, B. H. J. Juurlink, L. U. Thorpe and J. Alcorn, “Health Effects with Consumption of the Flax Lignan Secoisolariciresinol Diglucoside,” British Journal of Nutrition, Vol. 103, No. 7, 2010, pp. 929-938.
[36] G. Francis, Z. Kerem, H. P. S. Makkar and K. Becker, “The Biological Action of Saponins in Animal Systems: A Review,” British Journal of Nutrition, Vol. 88, No. 6, 2002, pp. 587-605.
[37] L. D. Lawson, “Duration of the Hypocholesterolemic Effect of Garlic Supplements,” JAMA Internal Medicine, Vol. 161, No. 20, 2001, pp. 2505-2506.
[38] H. P. Rang, M. M. Dale, J. M. Ritter and P. K. Moore, “Pharmacology,” 5th Edition, Elsevier, New Delhi, 2005.
[39] E. F. Al-Jumaily and Z. A. Auokty, “Reduction of Serum Hypercholesterolenic in Male Rabbits by Secoisolariciresinol Diglucoside (Lignan) Isolated from Flaxseed,” Trends in Life Sciences, Vol. 1, No. 1, 2012, pp. 6-11.
[40] T. Pereira, “Dyslipidemia and Cardiovascular Risk: Lipid Ratios as Risk Factors for Cardiovascular Disease,” In: R. Kelishadi, Ed., Dyslipidemia—From Prevention to Treatment, InTech, Rijeka, 2012, pp. 279-302.
[41] P. Greenland, J. S. Alpert, G. A. Beller, E. J. Benjamin, M. J. Budoff, Z. A. Fayad, E. Foster, M. A. Hlatky, J. M. Hodgson, F. G. Kushner, M. S. Lauer, L. J. Shaw, S. C. Smith Jr., A. J. Taylor, W. S. Weintraub, N. K. Wenger, A. K. Jacobs, S. C. Smith Jr., J. L. Anderson, N. Albert, C. E. Buller, M. A. Creager, S. M. Ettinger, R. A. Guyton, J. L. Halperin, J. S. Hochman, F. G. Kushner, R. Nishimura, E. M. Ohman, R. L. Page, W. G. Stevenson, L. G. Tarkington, C. W. Yancy and American College of Cardiology Foundation, American Heart Association, “2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, Vol. 122, No. 25, 2010, pp. e584-e636. or
[42] World Health Organization, “Prevention of Cardiovascular Disease. Guidelines for Assessment and Management of Cardiovascular Risk,” WHO Press, World Health Organization, Geneva, 2007.
[43] G. Assmann and A. M. Gotto Jr., “HDL Cholesterol and Protective Factors in Atherosclerosis,” Circulation, Vol. 109, Suppl. III, 2004, pp. III-8-III-14.
[44] D. McGrowder, C. Riley, E. Y. S. A. Morrison and L. Gordon, “The Role of High-Density Lipoproteins in Reducing the Risk of Vascular Diseases, Neurogenerative Disorders, and Cancer,” Cholesterol, Vol. 2011, 2001, Article ID: 496925.
[45] V. Zannis, A. Kateifides, P. Fotakis, E. Zanni and D. Kardassis, “Pleiotropic Functions of HDL Lead to Protection from Atherosclerosis and Other Diseases,” In: R. Kelishadi, Ed., Dyslipidemia—From Prevention to Treatment, InTech, Rijeka, 2012, pp. 172-198.
[46] K. Prasad, “Hypocholesterolemic and Antiatherosclerotic Effect of Flax Lignan Complex Isolated from Flaxseed,” Atherosclerosis, Vol. 179, No. 2, 2005, pp. 269-275.
[47] M. Miller, N. J. Stone, C. Ballantyne, V. Bittner, M. H. Criqui, H. N. Ginsberg, A. C. Goldberg, W. J. Howard, M. S. Jacobson, P. M. Kris-Etherton, T. A. Lennie, M. Levi, T. Mazzone and S. Pennathur, “Triglycerides and Cardiovascular Disease: A Scientific Statement from the American Heart Association,” Circulation, Vol. 123, No. 20, 2011, pp. 2292-2333.
[48] J. Frohlich and M. Dobiásová, “Fractional Esterification Rate of Cholesterol and Ratio of Triglycerides to HDLCholesterol Are Powerful Predictors of Positive Findings on Coronary Angiography,” Clinical Chemistry, Vol. 49, No. 11, 2003, pp. 1873-1880.
[49] M. Dobiásová, “Atherogenic Index of Plasma [Log (Triglyceride/HDL-Cholesterol)]: Theoretical and Practical Implications,” Clinical Chemistry, Vol. 50, No. 7, 2004, pp. 1113-1115.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.